JPH0873342A - Skin external preparation or bathing agent containing rubi fructus extract - Google Patents

Abstract

PURPOSE: To obtain a skin external preparation containing, as active ingredient, a Rubi fructus extract, free from skin irritancy, having antiallergic/anti- inflammatory activity such as histamine liberation-inhibitory activity, and high in safety, thus useful for preventing or remedying allergic skin inflammatory diseases. CONSTITUTION: This skin external preparation contains, as active ingredient, e.g. 0.001-10wt.% of an extract from Rubi fructus (e.g. Rubu schingii Hu). It is recommended, for example, that the extract be obtained by subjecting the plant's fruits to extraction, either directly or after dried, with a solvent such as water or an alcohol to obtain an extract which is then concentrated, diluted or evaporated to dryness, as the case may be.

Description

Detailed Description of the Invention

[0001]

INDUSTRIAL APPLICABILITY The present invention is effective for the prevention of allergic skin inflammatory diseases, the prevention and improvement of rough skin, the prevention of skin aging, and the high safety, which contains Phellinus linteus extract as an active ingredient. The present invention relates to a skin external preparation and a bath preparation. The skin external preparation or bath agent in the present invention is intended to prevent or improve skin and scalp troubles such as allergic skin inflammatory diseases (for example, redness, eczema, edema, swelling) and skin roughness. It means all external preparations. Specifically, liquids, emulsions, creams, ointments, gels, powders, granules, solids, or foams, 1) topical drugs, 2) quasi drugs, 3) topical or Skin cosmetics for the whole body, 4) Medicinal and / or cosmetic preparations applied to the scalp and hair (for example, shampoos, rinses, treatments, permanent liquids, hair styling agents, hair tonics, hair restoration and hair nourishing agents) Such),
5) Bath agents that can be used by throwing them in hot water.

[0002]

2. Description of the Related Art In recent years, allergic diseases such as bronchial asthma and allergic rhinitis are in a rapid increasing trend. Allergies are usually the function of the immune system that protects the body by eliminating foreign substances such as pathogenic microorganisms, and sometimes the reaction becomes hypersensitive, causing damage to the body and causing illness. It is a disorder reaction due to immune function and is currently classified into four types from type I to type IV.

The central cells constituting the immune system are a population of two types of lymphocytes called B cells and T cells, which are mainly present in bone marrow, thymus, spleen, lymph node, blood and the like. B
Cells are involved in humoral immunity (type I-III allergies),
In response to the antigen, it differentiates into plasma cells (antibody-producing cells), proliferates, and secretes the antibody extracellularly. Further, T cells are mainly involved in cell-mediated immunity (type IV allergy), and when they react with an antigen, they become activated T cells that differentiate and proliferate to destroy the antigen.

IgE antibodies are mainly involved in the type I allergic reaction. The onset process is the first step in which IgE antibodies are produced from B cells against foreign antigens and IgE antibodies are fixed to mast cells and basophils to form sensitization. Sensitized cells contacted with the antigen again. The second step in which chemical mediators such as histamine, serotonin, and SRS-A are released, and the released chemical mediators cause smooth muscle contraction, vascular permeability enhancement, edema, nerve stimulation, etc. It is roughly divided into the 3rd stage that develops allergic symptoms. Bronchial asthma, urticaria, pollen allergy and the like are known as type I allergic diseases.

The type II allergic reaction is a disorder reaction caused by destruction of tissue cells by IgG or IgM antibody. When an antibody binds to an antigen cell, the protein that composes the complement system is activated in a chain manner, and a complex that destroys the cell membrane is formed, so that the cell is destroyed. In addition, when the activated components of the complement system bind to cells, the antigen cells are captured and decomposed by phagocytic cells such as polymorphonuclear leukocytes and macrophages to be removed. On the other hand, in the process of activation of the complement system, a substance called anaphylatoxin, which has an action of remarkably promoting the decomposition of antigen by phagocytic cells, is produced. Since it also has the action of increasing the permeability of capillaries, the action of contracting smooth muscle, and the action of releasing histamine from mast cells, various allergic symptoms will be produced if it is excessively produced. Type II allergic diseases include drug allergies and hemolytic anemia.

The type III allergic reaction is mainly caused by IgG antibodies, and its onset occurs by a complex mechanism involving many factors such as the complement system and polymorphonuclear leukocytes. Antigen-antibody conjugates produced by binding antibodies to antigens are blood vessels, kidneys, joints,
It deposits in tissues such as skin and activates the complement system. When the amount of the conjugate is large, the complement system is excessively activated to produce anaphylatoxin, which increases vascular permeability and causes inflammation. In addition, when phagocytic cells work to remove antigen-antibody conjugates by the action of anaphylatoxin, degranulation reaction of lysosome occurs, and various types of hydrolytic enzymes such as protease in lysosome are released outside the tissue. And cell damage progresses, and type III allergy develops. Globular nephritis and serum diseases are classified as type III allergic diseases.

The type I to type III allergic reactions are all caused by humoral immunity, and the reaction appears in a few minutes after contact with the antigen, and the reaction reaches its maximum in a few ten minutes, so it is called immediate type. , Type IV allergic reaction appears after a few hours,
It takes 48 to 72 hours to reach the maximum, so it is called delayed allergy. This allergic reaction is a reaction caused by cell-mediated immunity, and a part of T cells reacts with an antigen to activate T
When they become cells, which react with the antigen again, they release various active proteins called lymphokines. Activated T cells and lymphokines act to activate macrophages and eliminate antigens, but excessive progress of this reaction causes allergic reaction as a disorder reaction. Symptoms of type IV allergy include tuberculin reaction and contact dermatitis.

Today, the most frequently occurring allergic diseases are allergic rhinitis caused by hay fever, mites, house dust, etc., food allergies caused by specific foods such as mackerel and eggs, allergic bronchial asthma,
Examples include atopic dermatitis. In particular, atopic dermatitis is attracting attention as one of the modern diseases, as its increase is exclaimed not only in children but also in a wide age group up to adults.

The conventionally used anti-allergic agents are agents for diseases caused by type I allergic reactions whose action points are relatively clear. For example, there are antispasmodics that relax smooth muscles, sympathomimetics that suppress hyperpermeability of capillaries, and antihistamines. These are drugs that act in the third stage, It is a symptomatic treatment. However, most of these drugs are synthetic drugs, and there is a problem in terms of side effects.

On the other hand, the most active researches on antiallergic agents involved in type I allergic diseases show an antagonistic effect on the released chemical mediators, which are agents that suppress the release of chemical mediators. The development of drugs that suppress the second stage, such as drugs, has not been found yet with sufficient efficacy.

Further, no specific antiallergic agent for type II and type III allergic reactions has been found, and complement is involved in these reactions. Therefore, studies on drugs having anticomplement activity were conducted. It's getting lost.

[0012]

In view of such circumstances, the present inventors have screened a substance that is excellent in antiallergic action, has no side effect, and is palliative for the skin from a plant which is a natural product. Tried. As a result, the bonito extract is highly safe and has a histamine release inhibitory effect.
The inventors have found that they have anti-allergic and anti-inflammatory effects such as metabolic activity suppressing action, anti-complement activity and hyaluronidase activity inhibiting action of arachidonic acid, and have completed the present invention. That is, an object of the present invention is to provide a skin external preparation or bath preparation excellent in prevention or improvement of skin / scalp troubles such as allergic skin inflammatory diseases (for example, redness, eczema, edema, swelling) and skin roughness. To provide.

[0013]

The present invention is an external preparation for skin and bath preparation, which contains an extract of Phellinus linteus as an active ingredient.

The bonobo used in the present invention means the Rosaceae (Rosaceae).
saceae) Plant strawberry rubuschingii Hu, Tokkuri strawberry R.coreanus Miq. or bear strawberry R.crataeg
The fruit of ifolius Bge. or its related plants. Mubonbonko is used as a Chinese medicine for vomiting, vomiting, and menstrual irregularity in China or South Korea. Regarding its anti-allergic and anti-inflammatory effects, and its application to external skin and bath agents, unknown.

The basal bud extract used in the present invention is the fruit of a plant as it is or after being dried and extracted with a solvent. Examples of the extraction solvent include water, alcohols (eg, lower alcohols such as methanol and ethanol, or polyhydric alcohols such as propylene glycol and 1,3-butylene glycol), ketones such as acetone, diethyl ether, dioxane, and the like. Esters such as acetonitrile and acetic acid ethyl ester, and organic solvents such as xylene, benzene, chloroform, and toluene can be used. When the extract is used as a dried product after removing the solvent, any of the above-mentioned solvents can be used alone or as a mixture, but when the extract is used in a state of being dissolved in the solvent, the human body It is preferable to use water, ethanol, 1,3-butylene glycol, or a mixed solvent thereof which is harmless to water. The extraction temperature may be in the range of the boiling point of the solvent at room temperature to atmospheric pressure. The obtained extract can be used by adding it to various preparations by concentrating or diluting or drying to dryness as needed.

[0016] The compounding amount of the Fukuroboshi extract in the present invention is
It is suitable to add 0.0001 to 20% by weight, preferably 0.001 to 10% by weight in terms of solid content in the total amount of the preparation. 0.000
If the amount is 1% by weight or less, no sufficient effect is observed, and if the amount is 20% by weight or more, the effect cannot be enhanced.

The skin external preparation or bath preparation of the present invention is, in addition to the Phellinus linteus extract, if necessary, a base or an additive which is usually used for the preparation of pharmaceuticals, quasi drugs, cosmetics and the like. It can be manufactured by combining agents. For example, oils include animal and vegetable oils, mineral oils, ester oils, wax oils, higher alcohols, fatty acids, silicone oils, phospholipids and the like. As the surface active agent, an anionic surface active agent, a cationic surface active agent, an amphoteric surface active agent, a nonionic surface active agent or the like is used. Others, p-aminobenzoic acid, anthranil derivative, salicylic acid derivative, coumarin derivative, amino acid compound, benzotriazole derivative, tetrazole derivative, imidazoline derivative, pyrimidine derivative, dioxane derivative, camphor derivative,
Furan derivative, pyrone derivative, nucleic acid derivative, allantoin derivative, nicotinic acid derivative, shikonin, vitamin B ₆
UV absorbers such as derivatives, ascorbic acid and its salts, stearic acid ester, tocopherol and its ester derivatives, nordihydroguaselethenoic acid, butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), parahydroxyanisole, gallic acid Antioxidants such as propyl, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, gum arabic, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methacrylate, polyacrylate,
Carboxyvinyl polymer, carrageenan, pectin,
Alginic acid and its salts, casein, thickeners such as gelatin, glycerin, propylene glycol, 1,3-butylene glycol, hyaluronic acid and its salts, polyethylene glycol, chondroitin sulfate and its salts, water-soluble chitin or chitosan derivative, sodium lactate. Moisturizers such as, lower alcohols, polyhydric alcohols, water-soluble polymers, pH adjusters, chelating agents, antiseptic / antifungal agents, fragrances, colorants, cooling agents, stabilizers, extractions originating from animals and plants Substances, animal / vegetable proteins and their degradation products, animal / vegetable polysaccharides and their degradation products, animal / vegetable glycoproteins and their degradation products, blood flow promoters, anti-inflammatory / anti-inflammatory agents, cell activating agents, vitamins , Amino acids and their salts, keratolytic agents,
Astringents, wound healing agents, foam boosters, deodorants / deodorants, etc. may be used in combination as necessary to produce the above-mentioned various products.

The external preparation for skin of the present invention can also be used in combination with a plant extract already known to have anti-inflammatory, anti-inflammatory and anti-allergic actions. For example, Arnica, Aloe, Angelica, Ichiakuso,
Turmeric, Squirrel, Squirrel, Cirrus, Hypericum, Steller's wort, Storm fir, Anemone, Kagosou, Cuckoo, Cleoptera, Birch, Chamomile, Kawara Mugwort, Glycyrrhoids, Pleurotus sacrum, Kakuhaku, Kakusawa, Kuwasa, Kakusa
Kotsaiho, burdock, salvia, sardine, antler, konjac, perilla, linden, zebra, peony, jiuyu, gall, zebra, syringa, horse mackerel, quintet, horse chestnut, nebulaceae, pacificus, velvetleaf, velvetleaf, hazelnut, hazelnut. Sendan, senburi, rhinoceros, pearl millet, thyme, thyme, dandelion, ginseng, chinpi, tsuwabuki, touka, touki, quince, tokusa, dokudami, tomato, trolloioi, elderberry, carrot, thistle, parsley, peppermint, linden,
Roses, hiss, juniper, loquats, butterburs, coltsfoot, wisteria, safflower, bodige, button pie, hops,
Horse chestnut, myrrh, succulent, merlot, melissa,
Examples include plant extracts such as peach, cornflower, mistletoe, mistletoe, eucalyptus, yukinoshita, yokinin, yomena, mugwort, lavender, gentian, forsythia, rosemary, and Roman chamomile. In addition, by using a combination of the Phellinus linteus extract of the present invention and these plant extracts,
An additive or synergistic anti-allergic / anti-inflammatory effect can be expected.

Further, the dosage form of the external preparation for skin of the present invention is arbitrary, and liquid medicines, emulsions, creams, ointments, gels, powders, granules, solids, bubbles, etc. , Quasi-drugs for external use, cosmetics for skin / hair, and bath agents. Specifically, basic cosmetics such as lotions, milky lotions, creams, ointments, oils, packs, facial cleansers, skin cleansers, shampoos, rinses, hair treatments, hair styling agents, perms, hair hernics, hair restoration and hair nourishing agents. Makeup cosmetics such as hair cosmetics, foundations, lipsticks, blushers, eye shadows, eyeliners, mascaras, etc., and liquid, powder and solid bath agents.

Regarding the method of adding the Fusumaria extract of the present invention to a skin external preparation or bath preparation, it may be added in advance or during the preparation, and may be appropriately selected in consideration of workability. Good.

[0021]

EXAMPLES Next, the present invention will be described in more detail with reference to production examples, test examples, and formulation examples, but it goes without saying that the present invention is not limited to these.

(Production Example 1) 100 g of bonito flakes were immersed in 1 L of a 50% ethanol solution, extracted at room temperature for 3 days and night, and suction-filtered to obtain an extract (dry solid content: 1.3 to 1.5% by weight).

(Production Example 2) 50 g of bonito flakes were mixed in an equal amount of a 30% ethanol solution and a 20% 1,3-butylene glycol solution 1
Gently heat-extract for about 6 hours at 50 ° C. with L to obtain an extract (dry solid content 1.0 to 1.2% by weight).

(Production Example 3) 100 g of bonito flakes and 500 ml of hexane
After immersing in room temperature at room temperature for 1 day, the solvent is distilled off, and the obtained paste-like substance is redissolved in 1 L of 30% propylene glycol solution and suction filtered to obtain an extract (dry solid content 0.9 to 1.0).

(Test 1) Measurement of histamine release inhibitory action In the type I allergic reaction, chemical mediators such as histamine are released from mast cells or basophils sensitized in the second step. Therefore, a substance that suppresses histamine release can be expected to have an antiallergic effect. In this test, a rat histamine-releasing reagent, co
Test method to release histamine with mpound 48/80 (J.Soc.C
osmet.Japan, Vol.25, No.4, P.246 (1992)) was used to examine the extract obtained in Production Example 1.

(Test method) a. After the solvent was distilled off from the sample extract under reduced pressure, the extract was redissolved in purified water to a solids concentration of 0.01, 0.1, and 0.5% by weight, and then subjected to the test. As a positive control, dipotassium glycyrrhizinate and sodium cromoglycate were used at the same concentration. b. Measurement of the amount of free histamine 0.5 ml of the sample was added to 3 ml of the mast cell suspension collected from the abdominal cavity of a rat (Slc: Wister male rat, about 7-9 weeks old).
And Compound 48/80 were added to a final concentration of 1 μg / ml and incubated at 37 ° C. for 15 minutes. After the reaction was stopped by cooling with ice, the reaction solution was centrifuged, histamine released from the supernatant was extracted and purified, and color was developed with o-phthaldialdehyde, and the fluorescence intensity at an excitation wavelength of 350 nm and a fluorescence wavelength of 450 nm was measured. The histamine release inhibition rate was calculated by the following formula.

[Equation 1]

(Test Results) As shown in Table 1, it was confirmed that the Phellinus linteus extract of the present invention has an excellent histamine release inhibiting effect as compared with dipotassium glycyrrhizinate or sodium cromoglycate.

[Table 1]

(Test 2) Arachidonic acid ear edema suppression test In the type I allergic reaction, phospholipids in the cell membrane are destroyed and arachidonic acid is released by the reaction of the IgE antibody with the antigen, and the chemical reaction is caused by the action of various enzymes. It is metabolized to prostaglandin, one of the transmitters, SRS-A, and as a result, various allergic symptoms are expressed. Therefore, the substance having the action of suppressing the metabolic activity of arachidonic acid can be expected to be used as an antiallergic agent. In this test, a hydrophilic ointment containing the extract obtained in Production Example 1 was formulated, and the method of Shinno et al. (“Effect of 3,4-Dihydroxychalcones on mouse arachidonic acid ear edema”: Japan Pharmaceutical Association No.
113 years meeting), the effect was examined.

(Test method) a. The sample extract was concentrated by distilling off the solvent under reduced pressure, and then a hydrophilic ointment containing an amount of 5,10% by weight in terms of solid content concentration was produced by a conventional method. An ointment containing dipotassium glycyrrhizinate was used as a positive control. b. Measurement of edema swelling rate The above ointment was applied in advance with arachidonic acid.
One hour before, a mouse (Slc: ICR female mouse, about 6 weeks old) was applied to the right auricle three times in total by carefully rubbing. Immediately before applying arachidonic acid, the ointment adhering to the auricle was wiped off, and 5 w / w% arachidonic acid (SIGMA) dissolved in acetone was used.
20 μl), and after 1 hour, punch out the auricles (5.0 m
m) did. Similarly, the left auricle was also excised, and the swelling rate of arachidonic acid ear edema was measured from the weight difference between the left and right auricles. The determination was made by comparing the ear edema swelling rate of the control group to which only the base was applied as a blank, and the ear edema inhibition rate was calculated. 8-9 mice were used for each test system.

(Test Results) As shown in Table 2, it was confirmed that the Phellinus linteus extract of the present invention showed an excellent inhibition rate over dipotassium glycyrrhizinate and had an action of inhibiting the metabolic activity of arachidonic acid.

[Table 2]

(Test 3) Measurement of anti-complement activity of basal bonito extract Since the complement system is greatly involved in type II and type III allergic reactions, the effect on allergy can be measured by measuring complement activity. It is possible to evaluate. In this test, the extract obtained in Production Example 1 was examined using an anti-complement action measuring method using the hemolytic reaction of sensitized red blood cells as an index.

(Test method) a. Gelatin / Veronal buffer (GVB ²⁺ ) Sodium chloride 1.7g, barbital 0.115g, barbital sodium 0.075g, calcium chloride 0.015g, magnesium chloride 0.010g, gelatin 0.2g, purified water 100ml are mixed and adjusted to pH 7.5. Then, the total volume was adjusted to 200 ml with purified water. b. Sheep erythrocyte (SRBC) suspension The sheep blood cells were centrifuged at 2,000 rpm for 5 minutes, washed 3 times with physiological saline, and GVB ²⁺ was added to the precipitate to make a 10% SRBC suspension, and finally SRBC. 3.05 in 0.25 ml suspension
When 0.1 ml of a 0.1% sodium carbonate solution was added for complete hemolysis, the absorbance at 540 nm was adjusted to 0.455. c. 0.2 ml of anti-SRBC mouse serum 10% SRBC suspension was intravenously injected into the tail of an IVCS male mouse, and 4 days after that, blood was collected and serum was separated.
It was used after being diluted 40-fold with B ²⁺ . d. Complement Guinea pig fresh serum was diluted 20-fold with GVB ²⁺ and used. e. After the solvent was distilled off from the sample extract under reduced pressure, the sample extract was redissolved in purified water to a solid content concentration of 0.5% by weight and used for the test. Dipotassium glycyrrhizinate was used as a positive control. f. Measurement of anti-complement activity 0.2 ml sample to 0.5 ml GVB ²⁺ and 0.5 ml anti-SRBC serum, S
After 0.25 ml of RBC suspension and 0.25 ml of complement solution were added successively, the reaction was carried out for 60 minutes in a constant temperature bath at 37 ° C. In ice water 10
After allowing the reaction to stand for a minute to stop the reaction, the reaction solution was centrifuged at 2,000 rpm for 10 minutes to separate unlysed red blood cells, and the OD value of the supernatant at 540 nm was measured. It should be noted that a sample containing purified water instead of the sample was used as a control, and a blank containing no serum was set for each sample and the control, and the complement inhibition rate (= anti-complement activity) was determined by the following formula.

(Equation 3)

(Test Results) As shown in Table 3, it was confirmed that the Phellinus linteus extract of the present invention has a stronger anti-complement activity than dipotassium glycyrrhizinate, and the effect of suppressing the development of type II and type III allergic symptoms. Can be expected.

[Table 3]

(Test 4) Measurement of hyaluronidase activity inhibitory effect Hyaluronidase is a hydrolase of hyaluronic acid distributed in connective tissue, and it is activated during inflammation and destroys the matrix of connective tissue to destroy cells and blood vessels of the inflammatory system. Is believed to play a role in increasing the permeability of It is also known as a inflammatory enzyme, and is also used as a inflammatory agent that experimentally induces acute edema. Furthermore, it has been reported that it is inhibited by anti-inflammatory agents and anti-allergic agents (inflammation, Vol.4, No.4, P.437 (1984)). It is possible to evaluate the anti-allergic effect. In this test, the inhibitory action of the extract obtained in Production Example 1 was examined with reference to the Morgan-Elson method.

(Test method) a. The solvent of the sample extract was distilled off under reduced pressure, and then the solid content concentration was adjusted with purified water.
It was redissolved to 0.5% and used for the test. Dipotassium glycyrrhizinate was used as a positive control. b. Measurement of hyaluronidase activity Hyaluronidase solution (final concentration 0.4 mg /
0.05 ml), leave it at 37 ℃ for 20 minutes, and then add Compound48 /
80 solution (final concentration 0.1 mg / ml) was added, and the mixture was allowed to stand at 37 ° C for 20 minutes, and then hyaluronic acid solution (final concentration 0.4 mg / m
l) 0.25 ml was added and left at 37 ° C. for 40 minutes. After stopping the reaction by adding 0.1 ml of 0.4N sodium hydroxide solution, 0.8M
0.1 ml of potassium borate solution was added and heated in boiling water for 3 minutes. After cooling to room temperature, add 3% of 1% p-dimethylaminobenzaldehyde acetic acid solution, leave at 37 ° C for 20 minutes, then
The absorbance at 85 nm was measured. In addition, a sample containing purified water instead of the sample was used as a control, a blank containing no enzyme was set for each sample and the control, and the hyaluronidase activity inhibition rate was calculated by the following formula.

[Equation 3]

(Test Results) As shown in Table 3, it was confirmed that the Phellinus linteus extract of the present invention has an excellent inhibitory effect on hyaluronidase activity comparable to that of glycyrrhizin dipotassium, and anti-inflammatory /
It can be judged to have an antiallergic effect.

(Test 5) Safety test (1) Primary skin irritation test The extracts obtained in Production Examples 1 to 3 had a dry solid content of about 20.
It was prepared so as to have a weight percentage, and this was applied to the skin of a rabbit whose back was shaved (3 animals per group, body weight around 3,800 g). The evaluation was carried out 24, 48, and 72 hours after application by using the erythema and edema as indices by the primary irritation scoring method. As a result, all animals were judged to be negative without any erythema or edema. (2) Skin cumulative irritation test The extract obtained in Production Examples 1 to 3 had a dry solid content of about 20.
Prepared so that the weight percentage becomes%, and remove the hair from the flank (2 x 4
cm ² ) Hartley guinea pig (female, 5 per group,
Skin (body weight: around 320 g) was applied once a day, 5 times a week, at 0.5 ml / animal. The application was carried out for 4 weeks, and the hair removal was performed on the last application day of each week. The determination was performed on the day after the last day of each week, using erythema and edema as indices by the primary scoring method. As a result, in all animals, 1-
Over 4 weeks, no erythema or edema was observed and the result was negative.

(Formulation Example 1) Lotion 1. Glycerin 5.0% by weight 2. Propylene glycol 4.0 3. Oleyl alcohol 0.1 4. Polyoxyethylene (20) sorbitan monolauric acid ester 1.5 5. Polyoxyethylene (20) lauryl ether 0.5 6. Ethanol 7.0 7. Hot-water extract of Ubonobushi 2.0 8. Preservative appropriate amount 9. Purified water residue

(Formulation Example 2) Emulsion 1. Squalane 5.0% by weight 2. Olive oil 5.0 3. Jojoba oil 5.0 4. Cetyl alcohol 1.5 5. Glycerin monostearate 2.0 6. Polyoxyethylene (20) cetyl ether 3.0 7. Poly Oxyethylene (20) soorbitan monooleate 2.0 8.1,3-butylene glycol 1.0 9. Glycerin 2.0 10. Bamboo root extract according to Production Example 1 3.0 11. Perfume, preservative appropriate amount 12. Purified water residue

(Formulation Example 3) Cream 1. Squalane 20.0% by weight 2. Beeswax 5.0 3. Refined jojoba oil 5.0 4. Glycerin monostearate 2.0 5. Polyoxyethylene (20) sorbitan monostearate 2.0 6. Sorbitan monostea Rate 2.0 7. Glycerin 5.0 8. Bamboo root extract according to Production Example 3.0 9. Fragrance, preservatives appropriate amount 10. Purified water Residue

(Formulation Example 4) Shampoo 1. 5.0% by weight triethanolamine lauryl sulfate 2. Polyoxyethylene lauryl ether sodium sulfate 12.0 3.1,3-butylene glycol 4.0 4. Diethanolamide laurate 2.0 5. Disodium edetate 0.1 6. Bamboo extract from Production Example 1.5 7. Appropriate amount of preservative 8. Purified water balance

(Formulation Example 5) Rinse 1. Cetyltrimethylammonium chloride 1.5% by weight 2. Cetanol 2.5 3. Squalane 2.0 4. Polyoxyethylene stearyl ether 1.0 5.1,3-butylene glycol 5.0 6. Bamboo spout extraction according to Production Example 1 Liquid 1.0 7. Fragrance, antiseptic proper amount 8. Purified water Residual

(Formulation Example 6) Hair tonic 1. L-menthol 0.2 2. Ethanol 32.5 3. Polyoxyethylene hydrogenated castor oil 0.5 4. Propylene glycol 5.0 5. Diphenhydramine hydrochloride 0.3 6. Bamboo sprouts extract according to Production Example 7.0 7 .Perfume, preservatives appropriate amount 8. Purified water residue

(Formulation Example 7) Face-wash cream 1. Stearic acid 10.0% by weight 2. Palmitic acid 10.0 3. Myristic acid 12.0 4. Lauric acid 4.0 5. Oleyl alcohol 1.5 6. Lanolin derivative (EO adduct) 1.0 7. Glycerin 18.0 8. Potassium hydroxide 6.0 9. Bamboo root extract according to Production Example 1.0 10. Perfume, preservatives appropriate amount 11. Purified water remaining amount

(Formulation Example 8) Cream foundation (W / O type) 1. Sorbitan sesquioleate 3.0% by weight 2. Self-emulsifying glyceryl monostearate 2.0 3. Aluminum stearate 0.5 4. Ceresin wax 5.0 5. Squalane 10.0 6. Liquid paraffin 15.0 7. Vaseline 5.0 8. Titanium oxide 8.0 9. Talc 4.0 10. Bamboo extract liquid according to Production Example 5.0 11. Color pigments, fragrances, preservatives proper amount 12. Preservative proper amount 13. Propylene glycol 5.0 14 .Purified water residue

(Formulation Example 9) Granular bath agent 1. Sodium hydrogencarbonate 45.0% by weight 2. Anhydrous sodium sulfate 40.0 3. Dried solid matter of Phellinus linteus extract according to Preparation Example 10.0 4. Appropriate amount of pigment and perfume

(Test 6) Use effect test The effect of actually using the external preparation for skin or bath agent of the present invention was examined. Use test is for skin diseases such as eczema, urticaria and atopic dermatitis 0-30
The test was carried out by applying the appropriate amount of the milky lotion of Prescription Example 2 to the face for 1 month after washing the face twice daily in the morning and in the evening with 5 panelists of 5 years old. In addition, 5 people (all children) with similar skin irritation on the scalp and hairline were subjected to a usage test by applying the hair nick of prescription example 6 to the scalp for 1 month after washing the hair daily. It was Furthermore, regarding a bath preparation containing the Fusumaria extract of Formulation Example 9, dry skin with dryness, skin diseases such as eczema and urticaria, and atopic dermatitis 1-45
A 20-year-old subject was asked to take a bath test in a bath with a bath agent dissolved for one month, and a monitor test was attempted. As controls, emulsions and shampoos were prepared by the same method with purified water except for the bonito extract, and bath agents prepared by the same method as described above, corrected by anhydrous sodium sulfate instead of the bonito extract.
No one complained of abnormal skin or scalp during the period of use.

The test results are shown in Table 3. The evaluation was performed according to the following criteria.・ Effect of improving skin (scalp) inflammation Effective: Redness and itch associated with inflammation such as eczema and rough skin improved somewhat Effective: Redness and itch associated with inflammation such as eczema, rough skin slightly improved Ineffective: Before use As is clear from the results in Table 4, it was confirmed that the use of the skincare external preparation containing the Fusumaria extract of the present invention has an excellent effect on skin inflammation.

[Table 4]

[0049]

INDUSTRIAL APPLICABILITY The basal radix extract of the present invention has no anti-allergic and anti-inflammatory effects such as histamine release inhibitory action, arachidonic acid metabolic activity inhibitory action, anti-complement activity and hyaluronidase activity inhibitory action without stimulating the skin. In addition, since it is highly safe, it can be applied to preparations in all forms (medicines, quasi drugs, cosmetics). In addition, the skin external preparation or bath preparation according to the present invention is an allergic skin inflammatory disease (eg, redness, eczema, edema, swelling, etc.)
It can be used for the purpose of prevention and improvement of skin and scalp that have troubles such as atopic dermatitis and rough skin, and it also prevents skin lumps and dullness, gives gloss and prepares texture. It is also effective in preventing skin aging.

[Equation 2]

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁶ Identification number Internal reference number FI Technical indication location A61K 7/075 ADA 7/08 7/50 35/78 AEM H 8217-4C (72) Inventor Ando Hiroshi 50, 6-6 Matsugaoka, Kakamigahara City, Gifu Prefecture

Claims (1)

[Claims] 1. A skin external preparation and a bath preparation, which contain an extract of Phellinus linteus as an active ingredient.